Publication Name	World Journal of Clinical Oncology
Manuscript ID	97823
Country	United States

Received	2024-06-10 03:51
Peer-Review Started	2024-06-10 03:51
To Make the First Decision
Return for Revision	2024-09-17 02:58
Revised	2024-10-21 01:13
Second Decision	2024-11-08 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-08 08:33
Articles in Press	2024-11-08 08:33
Publication Fee Transferred	2024-10-25 14:55
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-25 10:05
Publish the Manuscript Online	2024-12-11 10:19

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Phani Bhavana Cherukuri, Muhammad Tayyeb, Sai Rakshith Gaddameedi, Doantrang Du and Trishala Meghal
ORCID	Author(s) ORCID Number Phani Bhavana Cherukuri http://orcid.org/0009-0003-8562-0726
Funding Agency and Grant Number
Corresponding Author	Phani Bhavana Cherukuri, MD, Department of Internal Medicine, Monmouth Medical Center, 300 2nd Avenue, Long Branch, NJ 07740, United States. dr.bhavana.cherukuri22@gmail.com
Key Words	Pembrolizumab; Guillain-Barré syndrome; Triple-negative breast cancer; Immune-related adverse events; Intravenous immunoglobulin therapy; High-dose steroids; Case report
Core Tip	The immune checkpoint inhibitor pembrolizumab can cause rare immune-related adverse events like Guillain-Barré syndrome. This report details a patient with stage IIIB triple-negative breast cancer who developed Guillain-Barré syndrome after pembrolizumab treatment. Initial treatment with intravenous immunoglobulin was insufficient, but a combination of intravenous immunoglobulin and high-dose steroids led to significant improvement. This case highlights the importance of recognizing neurological complications in patients treated with pembrolizumab and emphasizes the need for timely diagnosis and multidisciplinary management of such complications.
Publish Date	2024-12-11 10:19
Citation	<p>Cherukuri PB, Tayyeb M, Gaddameedi SR, Du D, Meghal T. Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report. <i>World J Clin Oncol</i> 2025; 16(2): 97823</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i2/97823.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i2.97823

Full Article (PDF)	WJCO-16-97823-with-cover.pdf
CARE Checklist–2016	97823-CARE-Checklist-2016.pdf
Manuscript File	97823_Auto_Edited_031044.docx
Answering Reviewers	97823-answering-reviewers.pdf
Audio Core Tip	97823-audio.mp3
Conflict-of-Interest Disclosure Form	97823-conflict-of-interest-statement.pdf
Copyright License Agreement	97823-copyright-assignment.pdf
Signed Consent for Treatment Form(s) or Document(s)	97823-informed-consent-statement.pdf
Non-Native Speakers of English Editing Certificate	97823-non-native-speakers.pdf
Peer-review Report	97823-peer-reviews.pdf
Scientific Misconduct Check	97823-scientific-misconduct-check.png
Scientific Editor Work List	97823-scientific-editor-work-list.pdf
CrossCheck Report	97823-crosscheck-report.pdf